FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969951885> ?p ?o ?g. }

• W1969951885 endingPage "228" @default.
• W1969951885 startingPage "222" @default.
• W1969951885 abstract "To overcome gene therapy barriers such as low transfection efficiency and nonspecific delivery, liposomal nanoparticles targeted by a single-chain antibody fragment to the transferrin receptor (TfRscFv) delivering wild-type (wt) human p53 (SGT-53) were developed for tumor-specific targeting. We hypothesize that SGT-53 in combination with gemcitabine will demonstrate enhanced therapeutic benefit in an in vivo metastatic pancreatic cancer model. Intrasplenic injection of 1 × 106 Panc02 murine pancreatic cancer cells was used to generate in vivo hepatic metastatic tumors. Nanoparticle localization was assessed by tail vein injection of TfRscFv with fluorescently labeled oligonucleotides (6-carboxyfluorescein phosphoramidite (6FAM) ODN) imaged by Xenogen IVIS 200 scan. SGT-53 (equivalent to 30 μg of p53 intravenously) and gemcitabine (20 mg/kg intraperitoneally) alone and in combination were administered biweekly and compared with untreated mice. Survival was determined by blinded daily assessment of morbidity. Human wtp53 expression and transferrin levels in the tumors were assessed by western blot analysis. Tumor burden was quantified by liver weight. Xenogen imaging demonstrated tumor-specific uptake of TfRscFv-6FAM ODN. Exogenous human wtp53 protein was detected in the SGT-53-treated tumors compared with control. Compared with untreated mice with metastatic tumors demonstrating median survival of 20 days, SGT-53, gemcitabine and the combination demonstrated improved median survival of 29, 30 and 37 days, respectively. The combination treatment prolonged median survival when compared with single drug treatment and decreased tumor burden. The tumor targeting liposomal-based SGT-53 nanoparticle is capable of sensitizing pancreatic cancer to conventional chemotherapy in pancreatic cancer models. This approach has the potential to be translated into a new, more effective therapy for pancreatic cancer. Further optimization is ongoing, moving towards a Phase 1B/2 clinical trial." @default.
• W1969951885 created "2016-06-24" @default.
• W1969951885 creator A5000527734 @default.
• W1969951885 creator A5011910232 @default.
• W1969951885 creator A5022537592 @default.
• W1969951885 creator A5039264253 @default.
• W1969951885 creator A5047405531 @default.
• W1969951885 creator A5053441593 @default.
• W1969951885 creator A5055880560 @default.
• W1969951885 creator A5082575391 @default.
• W1969951885 creator A5083994081 @default.
• W1969951885 date "2013-03-08" @default.
• W1969951885 modified "2023-10-07" @default.
• W1969951885 title "Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy" @default.
• W1969951885 cites W112828355 @default.
• W1969951885 cites W1537583887 @default.
• W1969951885 cites W1931508686 @default.
• W1969951885 cites W1990832442 @default.
• W1969951885 cites W1998775946 @default.
• W1969951885 cites W2001019246 @default.
• W1969951885 cites W2019743927 @default.
• W1969951885 cites W2033520317 @default.
• W1969951885 cites W2039369340 @default.
• W1969951885 cites W2040306475 @default.
• W1969951885 cites W2042190607 @default.
• W1969951885 cites W2058548073 @default.
• W1969951885 cites W2061165346 @default.
• W1969951885 cites W2080323656 @default.
• W1969951885 cites W2103553318 @default.
• W1969951885 cites W2129204015 @default.
• W1969951885 cites W2138422753 @default.
• W1969951885 cites W2152183134 @default.
• W1969951885 cites W2160178368 @default.
• W1969951885 cites W2162067282 @default.
• W1969951885 cites W2164380696 @default.
• W1969951885 cites W2165948908 @default.
• W1969951885 cites W2171760054 @default.
• W1969951885 cites W4253192850 @default.
• W1969951885 doi "https://doi.org/10.1038/cgt.2013.9" @default.
• W1969951885 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3746039" @default.
• W1969951885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23470564" @default.
• W1969951885 hasPublicationYear "2013" @default.
• W1969951885 type Work @default.
• W1969951885 sameAs 1969951885 @default.
• W1969951885 citedByCount "92" @default.
• W1969951885 countsByYear W19699518852013 @default.
• W1969951885 countsByYear W19699518852014 @default.
• W1969951885 countsByYear W19699518852015 @default.
• W1969951885 countsByYear W19699518852016 @default.
• W1969951885 countsByYear W19699518852017 @default.
• W1969951885 countsByYear W19699518852018 @default.
• W1969951885 countsByYear W19699518852019 @default.
• W1969951885 countsByYear W19699518852020 @default.
• W1969951885 countsByYear W19699518852021 @default.
• W1969951885 countsByYear W19699518852022 @default.
• W1969951885 countsByYear W19699518852023 @default.
• W1969951885 crossrefType "journal-article" @default.
• W1969951885 hasAuthorship W1969951885A5000527734 @default.
• W1969951885 hasAuthorship W1969951885A5011910232 @default.
• W1969951885 hasAuthorship W1969951885A5022537592 @default.
• W1969951885 hasAuthorship W1969951885A5039264253 @default.
• W1969951885 hasAuthorship W1969951885A5047405531 @default.
• W1969951885 hasAuthorship W1969951885A5053441593 @default.
• W1969951885 hasAuthorship W1969951885A5055880560 @default.
• W1969951885 hasAuthorship W1969951885A5082575391 @default.
• W1969951885 hasAuthorship W1969951885A5083994081 @default.
• W1969951885 hasBestOaLocation W19699518851 @default.
• W1969951885 hasConcept C104317684 @default.
• W1969951885 hasConcept C111599444 @default.
• W1969951885 hasConcept C121608353 @default.
• W1969951885 hasConcept C126322002 @default.
• W1969951885 hasConcept C142724271 @default.
• W1969951885 hasConcept C143998085 @default.
• W1969951885 hasConcept C150903083 @default.
• W1969951885 hasConcept C185592680 @default.
• W1969951885 hasConcept C207001950 @default.
• W1969951885 hasConcept C22814914 @default.
• W1969951885 hasConcept C2776694085 @default.
• W1969951885 hasConcept C2780210213 @default.
• W1969951885 hasConcept C2780258809 @default.
• W1969951885 hasConcept C32264632 @default.
• W1969951885 hasConcept C502942594 @default.
• W1969951885 hasConcept C55493867 @default.
• W1969951885 hasConcept C71924100 @default.
• W1969951885 hasConcept C86803240 @default.
• W1969951885 hasConcept C98274493 @default.
• W1969951885 hasConceptScore W1969951885C104317684 @default.
• W1969951885 hasConceptScore W1969951885C111599444 @default.
• W1969951885 hasConceptScore W1969951885C121608353 @default.
• W1969951885 hasConceptScore W1969951885C126322002 @default.
• W1969951885 hasConceptScore W1969951885C142724271 @default.
• W1969951885 hasConceptScore W1969951885C143998085 @default.
• W1969951885 hasConceptScore W1969951885C150903083 @default.
• W1969951885 hasConceptScore W1969951885C185592680 @default.
• W1969951885 hasConceptScore W1969951885C207001950 @default.
• W1969951885 hasConceptScore W1969951885C22814914 @default.
• W1969951885 hasConceptScore W1969951885C2776694085 @default.
• W1969951885 hasConceptScore W1969951885C2780210213 @default.

• next